Alnylam Pharmaceuticals, Inc.
Explore Alnylam Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
ALNY — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Short-term liquidity looks comfortable.
Cons
- Leverage is relatively high.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Regeneron Pharmaceuticals, Inc. | $635.45 | 15.1 | $66.78 B | 0.6% | 10.23% | 14.32% | $821.11 / $476.49 | $295.71 |
| 2. | Royalty Pharma plc | $55.87 | 38.89 | $32.17 B | 1.71% | 8.21% | 12.67% | $56.07 / $33.37 | $11.22 |
| 3. | Revolution Medicines, Inc. | $149.23 | — | $31.73 B | — | -57.28% | -54.06% | $166.5 / $34 | $8.28 |
| 4. | Roivant Sciences Ltd. | $28.58 | — | $27.48 B | — | -21.06% | -6.85% | $32.79 / $10.71 | $6.28 |
| 5. | Insmed Incorporated | $94.22 | — | $21.48 B | — | -55.4% | -130.11% | $212.75 / $70.57 | $3.45 |
| 6. | Incyte Corporation | $102.38 | 14.53 | $20.8 B | — | 24.67% | 29.2% | $112.29 / $66.74 | $26.04 |
| 7. | Moderna, Inc. | $47.44 | — | $18.82 B | — | -29.7% | -36.73% | $59.55 / $22.28 | $21.95 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.1 B | 1.25 B | 773.69 M | 594.19 M | 593.17 M | — |
| Operating Profit | 131.72 M | 367.98 M | -16.2 M | 18.08 M | -105.16 M | — |
| Net Profit | 186.42 M | 251.08 M | -66.28 M | -57.48 M | -83.76 M | — |
| EPS in Rs | 1.4 | 1.88 | -0.5 | -0.43 | -0.63 | -0.87 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.71 B | 2.25 B | 1.83 B | 1.04 B |
| Operating Profit | 501.58 M | -176.88 M | -282.18 M | -785.07 M |
| Net Profit | 313.75 M | -278.16 M | -440.24 M | -1.13 B |
| EPS in Rs | 2.35 | -2.08 | -3.3 | -8.48 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 4.97 B | 4.24 B | 3.83 B | 3.55 B |
| Total Liabilities | 4.18 B | 4.17 B | 4.05 B | 3.7 B |
| Equity | 789.18 M | 67.09 M | -220.64 M | -158.22 M |
| Current Assets | 4.05 B | 3.3 B | 2.98 B | 2.69 B |
| Current Liabilities | 1.47 B | 1.19 B | 967.79 M | 767.91 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 524.08 M | -8.31 M | 104.16 M | -541.27 M |
| Investing CF | 436.33 M | -116.84 M | -336.35 M | 169.35 M |
| Financing CF | -305.19 M | 294.16 M | 172.13 M | 425.75 M |
| Free CF | 465.38 M | -42.59 M | 41.95 M | -613.33 M |
| Capex | -58.7 M | -34.28 M | -62.21 M | -72.06 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 65.19% | 22.97% | 76.23% | — |
| Earnings Growth % | 212.79% | 36.82% | 61.08% | — |
| Profit Margin % | 8.45% | -12.37% | -24.08% | -109.04% |
| Operating Margin % | 13.51% | -7.87% | -15.43% | -75.68% |
| Gross Margin % | 81.64% | 85.62% | 83.02% | 83.73% |
| EBITDA Margin % | 17% | -7.95% | -14.12% | -89.31% |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.
Frequently Asked Questions — Alnylam Pharmaceuticals, Inc.
Will Alnylam Pharmaceuticals, Inc. stock hit $364 in 2026?
Alnylam Pharmaceuticals, Inc. (ALNY) is currently trading at $303.05, with a 52-week range of $283.1 to $495.55. Reaching the $364 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Wall Street analysts currently have a consensus price target of $449.0 for Alnylam Pharmaceuticals, Inc., with a Buy rating, and the most bullish analysts see the stock reaching as high as $566.0. Whether Alnylam Pharmaceuticals, Inc. can reach $364 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Historically, ALNY has delivered a 15.6% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the ALNY Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is Alnylam Pharmaceuticals, Inc. stock worth buying at $303.05?
Whether Alnylam Pharmaceuticals, Inc. (ALNY) is worth buying at $303.05 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: Alnylam Pharmaceuticals, Inc. trades at a Price-to-Earnings (P/E) ratio of 70.4x, which can be compared against other Healthcare companies to assess whether the stock is expensive or attractively priced relative to its peers.
Profitability & efficiency: Alnylam Pharmaceuticals, Inc. has a Return on Capital Employed (ROCE) of 14.3%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at 98.3%, suggesting management is effectively converting shareholder equity into profit.
Financial health: The Debt-to-Equity ratio of 376.19 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.
Analyst view: The Wall Street consensus recommendation for ALNY is currently Buy, with a mean price target of $449.0 based on 25 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for Alnylam Pharmaceuticals, Inc. (ALNY) in 2026?
As of 2026, Wall Street analysts have set a consensus (mean) price target of $449.0 for Alnylam Pharmaceuticals, Inc. (ALNY), aggregated from 25 analyst ratings. The overall analyst recommendation is Buy.
The price target range spans from $310.0 on the bearish end to $566.0 on the most optimistic projection, with a median target of $448.0. This wide range reflects differing views on Alnylam Pharmaceuticals, Inc.'s growth prospects, competitive positioning, and macroeconomic sensitivity.
It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the ALNY analysis page on StockSifting.
Is Alnylam Pharmaceuticals, Inc. overvalued at a P/E ratio of 70.4x?
Alnylam Pharmaceuticals, Inc. (ALNY) currently has a Price-to-Earnings (P/E) ratio of 70.4x, meaning investors are paying $70.4 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:
Sector context: The Healthcare sector tends to command higher valuation multiples when growth expectations are elevated. A 70.4x P/E is on the higher end, suggesting the market is pricing in continued strong earnings growth — any disappointment in future earnings could lead to a multiple contraction.
Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation. Alnylam Pharmaceuticals, Inc.'s ROCE of 14.3% suggests it has moderate capital returns.
Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of ALNY's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.
What will Alnylam Pharmaceuticals, Inc. stock be worth in 2029?
Projecting Alnylam Pharmaceuticals, Inc. (ALNY)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.
Based on ALNY's historical 5-year Compound Annual Growth Rate (CAGR) of 15.6%, if that rate of growth were to continue, the stock could reach approximately $468 by 2029 — up from its current price of $303.05. This projection assumes the historical CAGR holds, which depends on Alnylam Pharmaceuticals, Inc. sustaining its revenue growth, maintaining profit margins, and the market continuing to reward it at a similar valuation multiple.
In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.
You can model different scenarios — conservative, base, and bull case — using the ALNY Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.